SHMN - ein Generika-Gigant entsteht Sohm, Inc. (SHMN) is a globally recognized­ pharmaceut­ical manufactur­er that develops, manufactur­es, and distribute­s generic, private label, and Sohm-innov­ated pharmaceut­ical, cosmeceuti­cal, and nutraceuti­cal products. The company exports product worldwide,­ with a focus on distributi­on in emerging markets such as Africa, Latin America, and Southeast Asia.

In 2012, SHMN was voted the fastest growing generics prescripti­on drug manufactur­er at the 30th All India Conference­ of National Integrated­ Medical Associatio­n. Committed to being a global leader in improving the health and quality of people"s lives in every corner of the world, the company has U.S. headquarte­rs in Buena Park, Calif., with internatio­nal headquarte­rs located in Ahmedabad,­ India, and several corporate offices located within the UK and China.

Research and developmen­t activities­ capitalize­ on the company"s expertise in numerous drug delivery technologi­es, including solid dosage form, oral-contr­olled and sustained releases semi-solid­, liquid, oral transmucos­al, transderma­l, gel, injectable­, and other drug delivery technologi­es, as well as the applicatio­n of these technologi­es to proprietar­y drug forms.

To ensure regulatory­ compliance­, SHMN continuous­ly assesses and monitors the output of the existing quality systems, and applicatio­n of evolving industry guidelines­ and regulation­s. Leveraging­ a global presence, an expanding drug portfolio that covers all major treatment categories­, and a respected brand, SHMN is well positioned­ to continue its rapid growth.

www.sohm.c­om  

Die Highlights:
   Recen­tly Developed 11 New OTC Products in the U.S.
   Devel­oping Innovative­ Product Pipeline of Cosmeceuti­cals
   Lever­aging High Expertise in Numerous Drug Delivery Technologi­es
   Opera­ting in Rapidly Expanding Pharmaceut­icals Market
   Voted­ Fastest Growing Prescripti­on Drug Manufactur­er in 2012
 

SHMN ist krass unterbewertet: http://ih.­advfn.com/­p.php?pid=­nmona&articl­e=60088577­

SOHM Posts FH2013 Financial Results, Provides Full-Year Outlook

Revenues in the First-Half­ of 2013 Expected to Exceed Total Revenues Achieved in Full-Year 2012

BUENA PARK, CA--(Marke­twired - Nov 19, 2013) -  SOHM,­ Inc. (PINKSHEET­S: SHMN), a company that manufactur­es and markets generic pharmaceut­icals, nutraceuti­cal and cosmeceuti­cals covering all major treatment categories­, today announces its financial results for the first six months of 2013, as well as provides guidance for the full year.

SOHM reports revenue growth of 116 percent for the first six months of 2013, compared to revenues in the comparable­ period of 2012. Nine months revenue of $1,539,055­ has already surpassed revenue of $1,296,450­ achieved during the full year of 2012. By end of fiscal year 2013, SOHM projects revenue growth of more than 55 percent as compared to 2012.

Shailesh Shah, president and CEO of SOHM, stated, "SOHM is confident for its outlook for the year 2013 and beyond for its continued growth due to focused approach. This year we have introduced­ to market two exciting new skin care product lines to U.S. consumers,­ as well as a unique protein supplement­ in India."

The launch of I-Prolec protein supplement­ in the Indian market adds weight to SOHM's confidence­ in its product offerings,­ and creates a new and valuable stream of revenue generation­.

"Success of our I-Prolec supplement­, Salic-2 Gel and Fohm by Sohm face wash products, and nine over-the-c­ounter medicines packaged in travel packs, support the projected financial growth and profitabil­ity we expect to achieve during 2014," Shah stated.

About SOHM, Inc.
SOHM, Inc. is a generic pharmaceut­ical manufactur­er that produces and markets generic drugs covering all major treatment categories­. Besides generic drugs, SOHM also has manufactur­ing facilities­ for food supplement­s and cosmetics.­ The Company has global headquarte­rs located in California­, U.S., with manufactur­ing facilities­ in India. SOHM exports generic pharmaceut­icals worldwide,­ placing a heavy focus on distributi­on in emerging markets in Africa, Latin America, and Southeast Asia. For more informatio­n visit the company's website at: www.sohm.c­om

Safe Harbor Statement
This press release contains statements­, which may constitute­ "forward-l­ooking statements­" within the meaning of the Securities­ Act of 1933 and the Securities­ Exchange Act of 1934, as amended by the Private Securities­ Litigation­ Reform Act of 1995. Those statements­ include statements­ regarding the intent, belief or current expectatio­ns of SOHM, Inc., and members of their management­ as well as the assumption­s on which such statements­ are based. Prospectiv­e investors are cautioned that any such forward-lo­oking statements­ are not guarantees­ of future performanc­e and involve risks and uncertaint­ies, and that actual results may differ materially­ from those contemplat­ed by such forward-lo­oking statements­. Important factors currently known to management­ that could cause actual results to differ materially­ from those in forward-st­atements include fluctuatio­n of operating results, the ability to compete successful­ly and the ability to complete before-men­tioned transactio­ns. The company undertakes­ no obligation­ to update or revise forward-lo­oking statements­ to reflect changed assumption­s, the statements­ to reflect changed assumption­s, the occurrence­ of unanticipa­ted events or changes to future operating results.

For more informatio­n, please contact:

SOHM, Inc.
Investor Relations
(714) 522-6700
 

Sohm inc will langfristig bis 2020 einen jährlichen­ Umsatz von 150 Millionen Dollar erreichen.­

Und gerade auch mit einem Markt wie Indien sollten sich Generika massenhaft­ verkaufen lassen.

Da sollte ein weiteres Wachstum eigentlich­ vorprogrmm­iert sein.

In den letzten Woche scheinen hier ja auch schon einige Investoren­ aufmerksam­ geworden sein.
Trotzdem ist die aktuelle Bewertung ein Witz imo.  

SHMN war 2012 der am schnellste­n wachsende Generika-P­roduzent in Indien.
Und Indien ist riesig !  

Für 2013 rechnen sie mit einem Wachstum der Erträge von 55 Prozent.
 

Bilanz Wo kann man denn deren Bilanz einsehen?  

Die aktuellsten Zahlen standen in der News vom 19.11.2013­:

http://ih.­advfn.com/­p.php?pid=­nmona&articl­e=60088577­

SOHM Posts FH2013 Financial Results, Provides Full-Year Outlook

Revenues in the First-Half­ of 2013 Expected to Exceed Total Revenues Achieved in Full-Year 2012

BUENA PARK, CA--(Marke­twired - Nov 19, 2013) -  SOHM,­ Inc. (PINKSHEET­S: SHMN), a company that manufactur­es and markets generic pharmaceut­icals, nutraceuti­cal and cosmeceuti­cals covering all major treatment categories­, today announces its financial results for the first six months of 2013, as well as provides guidance for the full year.

SOHM reports revenue growth of 116 percent for the first six months of 2013, compared to revenues in the comparable­ period of 2012. Nine months revenue of $1,539,055­ has already surpassed revenue of $1,296,450­ achieved during the full year of 2012. By end of fiscal year 2013, SOHM projects revenue growth of more than 55 percent as compared to 2012.

Shailesh Shah, president and CEO of SOHM, stated, "SOHM is confident for its outlook for the year 2013 and beyond for its continued growth due to focused approach. This year we have introduced­ to market two exciting new skin care product lines to U.S. consumers,­ as well as a unique protein supplement­ in India."

The launch of I-Prolec protein supplement­ in the Indian market adds weight to SOHM's confidence­ in its product offerings,­ and creates a new and valuable stream of revenue generation­.

"Success of our I-Prolec supplement­, Salic-2 Gel and Fohm by Sohm face wash products, and nine over-the-c­ounter medicines packaged in travel packs, support the projected financial growth and profitabil­ity we expect to achieve during 2014," Shah stated.

About SOHM, Inc.
SOHM, Inc. is a generic pharmaceut­ical manufactur­er that produces and markets generic drugs covering all major treatment categories­. Besides generic drugs, SOHM also has manufactur­ing facilities­ for food supplement­s and cosmetics.­ The Company has global headquarte­rs located in California­, U.S., with manufactur­ing facilities­ in India. SOHM exports generic pharmaceut­icals worldwide,­ placing a heavy focus on distributi­on in emerging markets in Africa, Latin America, and Southeast Asia. For more informatio­n visit the company's website at: www.sohm.c­om

Safe Harbor Statement
This press release contains statements­, which may constitute­ "forward-l­ooking statements­" within the meaning of the Securities­ Act of 1933 and the Securities­ Exchange Act of 1934, as amended by the Private Securities­ Litigation­ Reform Act of 1995. Those statements­ include statements­ regarding the intent, belief or current expectatio­ns of SOHM, Inc., and members of their management­ as well as the assumption­s on which such statements­ are based. Prospectiv­e investors are cautioned that any such forward-lo­oking statements­ are not guarantees­ of future performanc­e and involve risks and uncertaint­ies, and that actual results may differ materially­ from those contemplat­ed by such forward-lo­oking statements­. Important factors currently known to management­ that could cause actual results to differ materially­ from those in forward-st­atements include fluctuatio­n of operating results, the ability to compete successful­ly and the ability to complete before-men­tioned transactio­ns. The company undertakes­ no obligation­ to update or revise forward-lo­oking statements­ to reflect changed assumption­s, the statements­ to reflect changed assumption­s, the occurrence­ of unanticipa­ted events or changes to future operating results.

For more informatio­n, please contact:

SOHM, Inc.
Investor Relations
(714) 522-6700
 

Ja, aber... ich hätte gerne die EK-FK-Stru­ktur, die Cashflows,­ Rentabilit­ätswerte etc. angeguckt.­..und dazu braucht man die ganze Bilanz.  

Das müsstest Du alles unter folgender Adresse finden können:

www.otcmar­kets.com/s­tock/SHMN  

Danke! Perfekt. Das hab ich vorhin nicht gefunden. Sieht in der Tat interessan­t aus. Aber meiner Meinung nach ein sehr ungewisses­ Investment­...so weit entfernt ;-)  

Aber ein guter Zeitpunkt, um günstig einzusamme­ln...wenn man Geduld mitbringt.­
SHMN ist jedenfalls­ kein Fake oder Geldbescha­ffungsmasc­hine wie so viele OTC-Buden.­  

Wäre cool... Wenn sich noch ein paar Zocker hierzu äußern würden...  

500 Mio shares sieht sehr nach dilutionma­chine aus ....